ALNY Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

1.18B

+98.51%

1.327

-304.09%

1.24B

+109.33%

1.500

-440.91%

1.38B

+77.72%

1.752

-443.63%

Estimates Revision

The market is revising Upward the revenue expectations for Alnylam Pharmaceuticals, Inc. (ALNY) for FY2025, with the revenue forecasts being adjusted by 5.45% over the past three months. During the same period, the stock price has changed by -12.84%.

Revenue Estimates for FY2025

Revise Upward

+5.45%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+102.69%

In Past 3 Month

Stock Price

Go Down

-12.84%

In Past 3 Month

21 Analyst Rating

Wall Street analysts forecast ALNY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALNY is 497.68 USD with a low forecast of 370.00 USD and a high forecast of 570.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

17 Buy

4 Hold

0 Sell

Strong Buy

Current: 0.000

Low

370.00

Averages

497.68

High

570.00

Current: 0.000

Low

370.00

Averages

497.68

High

570.00

Truist

Buy

downgrade

$535 -> $530

2026-01-08

New

Reason

Truist

Price Target

$535 -> $530

2026-01-08

New

downgrade

Buy

Reason

Truist lowered the firm's price target on Alnylam to $530 from $535 and keeps a Buy rating on the shares. The firm updated its model, but tells investors in a research note that the fundamental views remain intact from 2025.

Oppenheimer

Outperform

initiated

$500

2026-01-07

New

Reason

Oppenheimer

Price Target

$500

2026-01-07

New

initiated

Outperform

Reason

Oppenheimer assumed coverage of Alnylam with an Outperform rating and $500 price target. The firm says Amvuttra's uptake in ATTR-CM has been impressive, delivering about $300M sales in its second full quarter post-launch. Despite Amvuttra's strong growth, Alnylam has been under pressure, mainly due to market concerns around potential deceleration of Amvuttra growth and elevating payer pushback. Although Oppenheimer anticipates Q4 2025 seasonality to impact Amvuttra sales, the firm thinks Amvuttra will continue to beat growth expectations in Q4 and beyond and anticipates upcoming sales/guidance announcements to drive 10%-20% upside in Alnylam.

Bernstein

Outperform

NULL

downgrade

$525 -> $491

2026-01-06

New

Reason

Bernstein

Price Target

$525 -> $491

2026-01-06

New

downgrade

Outperform

NULL

Reason

Bernstein lowered the firm's price target on Alnylam to $491 from $525 and keeps an Outperform rating on the shares. The firm notes Alnylam has pulled back 12% since the end of November based on third-party data suggesting the ATTR-CM launch has stalled. With recent IQVIA data telling a similar story as Symphony, Bernstein is cutting its numbers ahead of next week's planned pre-announcement of Q4 results.

Leerink

Mani Foroohar

Market Perform

downgrade

$370 -> $351

2025-12-15

Reason

Leerink

Mani Foroohar

Price Target

$370 -> $351

2025-12-15

downgrade

Market Perform

Reason

Leerink analyst Mani Foroohar lowered the firm's price target on Alnylam to $351 from $370 and keeps a Market Perform rating on the shares. Heading into 2026, the firm is refreshing its TTR market outlookafter strong launches from BridgeBio's (BBIO) Attruby and Alnylam's (ALNY) Amvuttra. Leerink expects continued robust growth in 2026, supported by end-market tailwinds from improved diagnosis rates leading to earlier treatment, but is keeping tabs on payer/reimbursement dynamics and pace of new patient adds/switches.

Leerink

Outperform

maintain

$85 -> $100

2025-12-15

Reason

Leerink

Price Target

$85 -> $100

2025-12-15

maintain

Outperform

Reason

Leerink raised the firm's price target on Ionis Pharmaceuticals (IONS) to $100 from $85 and keeps an Outperform rating on the shares. Heading into 2026, the firm is refreshing its TTR market outlook after strong launches from BridgeBio's (BBIO) Attruby and Alnylam's (ALNY) Amvuttra. Leerink expects continued robust growth in 2026, supported by end-market tailwinds from improved diagnosis rates leading to earlier treatment, but is keeping tabs on payer/reimbursement dynamics and pace of new patient adds/switches.

Stifel

NULL

Buy

maintain

$495 -> $508

2025-12-11

Reason

Stifel

Price Target

$495 -> $508

2025-12-11

maintain

NULL

Buy

Reason

Stifel raised the firm's price target on Alnylam to $508 from $495 and keeps a Buy rating on the shares. The firm "refreshed diligence" on many companies within its biotechnology coverage universe and made a number of model, estimate and price target changes in a 2026 look ahead note for the group.

Valuation Metrics

The current forward P/E ratio for Alnylam Pharmaceuticals Inc (ALNY.O) is 60.41, compared to its 5-year average forward P/E of -43.52. For a more detailed relative valuation and DCF analysis to assess Alnylam Pharmaceuticals Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-43.52

Current PE

60.41

Overvalued PE

27.85

Undervalued PE

-114.90

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-7444.00

Current EV/EBITDA

43.64

Overvalued EV/EBITDA

51136.61

Undervalued EV/EBITDA

-66024.61

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

15.35

Current PS

10.01

Overvalued PS

19.32

Undervalued PS

11.38

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

ALNY News & Events

Events Timeline

No data

News

7.5

01-07Yahoo Finance

Scenic Biotech Partners with Ono Pharmaceutical for Cell-Seq Platform Licensing

5.0

01-02Benzinga

Vertiv Holdings Co. Expected to Join S&P 500 in Q1 2026 with Nearly $62 Billion Market Cap

7.0

2025-12-31Barron's

Earnings Warning Season is Here: Strategies to Benefit from Others' Struggles.

People Also Watch

Frequently Asked Questions

What is Alnylam Pharmaceuticals Inc (ALNY) stock price today?

The current price of ALNY is 398.29 USD — it has decreased -0.28 % in the last trading day.

What is Alnylam Pharmaceuticals Inc (ALNY)'s business?

Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.

What is the price predicton of ALNY Stock?

What is Alnylam Pharmaceuticals Inc (ALNY)'s revenue for the last quarter?

Alnylam Pharmaceuticals Inc revenue for the last quarter amounts to 1.25B USD, increased 149.35 % YoY.

What is Alnylam Pharmaceuticals Inc (ALNY)'s earnings per share (EPS) for the last quarter?

Alnylam Pharmaceuticals Inc. EPS for the last quarter amounts to 1.83 USD, decreased -310.34 % YoY.

What changes have occurred in the market's expectations for Alnylam Pharmaceuticals Inc (ALNY)'s fundamentals?

How many employees does Alnylam Pharmaceuticals Inc (ALNY). have?

Alnylam Pharmaceuticals Inc (ALNY) has 2230 emplpoyees as of January 10 2026.

What is Alnylam Pharmaceuticals Inc (ALNY) market cap?

Today ALNY has the market capitalization of 52.62B USD.